<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24215">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791516</url>
  </required_header>
  <id_info>
    <org_study_id>20150242</org_study_id>
    <nct_id>NCT02791516</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study to Evaluate AMG 785 in South Korean Women With Osteoporosis.</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of
      6 months treatment with Romosozumab compared to placebo by determining the percent changes
      in bone mineral density
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in women
      with osteoporosis. The study is designed to evaluate if treatment with Romosozumab (AMG 785)
      once a month for 6 months compared with placebo is effective in increasing bone mineral
      density.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in bone mineral density at the lumbar spine at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Measure the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy x-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone mineral density at the total hip at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Measure the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in DXA BMD at the total hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone mineral density at the femoral neck at 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Measure the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in DXA BMD at the femoral neck.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postmenopausal Osteoporosis (PMO)</condition>
  <arm_group>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm is to receive monthly SC injections of Romosozumab (AMG 785).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm is to receive monthly SC injections of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Subcutaneous injections of Romosozumab monthly for 6 months.</description>
    <arm_group_label>Romosozumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injections of placebo monthly for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory postmenopausal Korean women, ≥ 55 to ≤ 90 years of age at enrollment.

          -  Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or
             more consecutive months prior to screening.

          -  BMD T-score &lt;/= -2.50 at the lumbar spine, total hip or femoral neck.

          -  At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable
             by DXA.

          -  Other inclusion criteria may apply.

        Exclusion Criteria:

          -  Subjects with a BMD T-score &lt;/= -4.0 at the lumbar spine, total hip, or femoral neck.

          -  History of hip fracture.

          -  Bone disease other than osteoporosis/ or evidence of any other clinically significant
             disorder, condition/ or disease or significant laboratory abnormalities.

          -  Known sensitivity or intolerance calcium and vitamin D products.

          -  Other exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Namdong-gu, Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si, Gyeonggi-do</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>June 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis.</keyword>
  <keyword>Osteoporosis-Postmenopausal.</keyword>
  <keyword>Bone Diseases-Metabolic.</keyword>
  <keyword>Bone Diseases.</keyword>
  <keyword>Musculoskeletal Diseases.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
